哎，我们的汤森账户过期了，不能帮助啊。
LCL161 is a potent mimetic of Smac (a protein that is released from the mitochondria) that binds to inhibitor of apoptosis proteins (IAPs) with high affinity and initiates the destruction of cellular inhibitor of apoptosis proteins (CIAP1 and CIAP2). LCL161 kills tumor cells via activation of caspases. LCL161 is indicated for the treatment of advanced solid tumors and breast cancer.
Indications (current phase): Breast Cancer(II), Solid Tumors(I)
LCL161是Novartis的化合物，核心专利US 8552003，失效日期05/13/2029。有两篇中国同族专利获授权
CN101511860B，申请日：2007.07.31
CN102558165B，申请日：2007.07.31
楼主现在做是不是有点太早了啊！
